Seven children in India diagnosed with Allan-Herndon-Dudley syndrome (AHDS), also known as MCT8 deficiency, are expected to receive a year's supply of tiratricol free of cost on November 30. The initiative has addressed a major financial barrier associated with treatment of this rare genetic disorder. The effort was initiated by Hyderabad-based paediatrician Dr.

Sivaranjani Santosh, in collaboration with Access to Medicines India, after a child under her care was diagnosed with AHDS and the family struggled to afford the medicine. The development is particularly significant because the estimated annual cost of the commercially available medicine ranges from approximately ₹4.68 crore to ₹9 crore per child. Through pharmaceutical compounding in the Netherlands, the estimated cost has been reduced to approximately ₹2.5 lakh per child for one year of treatment.The formulation has been…